Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial

Jefferies raised its AstraZeneca price target to 18,000p (from 15,000p) and reiterated a buy after reversing its stance on the phase III AVANZAR trial for datopotamab deruxtecan plus Imfinzi and chemo, boosting the trial success probability from 40% to 60% and noting two delays likely reflect stronger-than-expected survival in the active arm versus the Keytruda+chemo control. The broker said the higher success odds materially improve revenue prospects—particularly for Imfinzi in the combination setting—and highlighted AZ’s leading platforms (cell therapy, inhaled biologics, T-cell engagers), noting >$2.5bn of M&A to build cell therapy assets that could add $5–$10bn by decade-end; Jefferies estimates AZ needs ~£12.5bn of incremental revenues by 2034 beyond an £80bn 2030 target. Shares were quoted flat at 14,688p.

Analysis

Market structure: Jefferies' reinterpretation of AVANZAR shifts winners to AZN (directly) and Imfinzi combination economics, while Merck (MRK) is a tactical loser in advanced NSCLC share if survival advantage materialises; drug-pricing dynamics for frontline NSCLC could tighten but total addressable market may expand. Cross-asset: positive AZN outcome would tighten AZN credit spreads, be mildly GBP-positive and lift biotech risk assets; failure would widen AZN CDS and depress European pharma equities.

Risk assessment: Tail risks include a negative AVANZAR readout, unexpected ADC toxicities (ILD) triggering label restrictions, or regulatory/payer pushback on combination pricing; probability-weight these as 20–30% downside events with >30% share-price drawdown. Time horizons: immediate (days) — limited reaction to upgrade; short (weeks–months) — rising IV into H2 2026 readout; long (years) — platform execution (cell therapy/TCEs) drives $5–10bn upside by 2030 conditional on multiple positive trials. Hidden dependencies: success hinges on OS separation vs Keytruda control, biomarker cohorts, and reimbursement decisions; DMC comments and interim survival curves are high-leverage signals.

Trade implications: Favor asymmetric exposure to AZN ahead of H2 2026 readout: equity plus defined-risk options rather than naked long. Consider pair trades vs MRK to isolate oncology outcome risk and use protective puts or spread structures to cap downside as volatility re-prices. Sector rotation: overweight large-cap European pharma/bio with durable pipelines, underweight small-cap ADC developers with single-trial dependence.

Contrarian angles: Consensus treats delay as positive — it can also reflect operational or censoring issues; Jefferies' P(success) lift to 60% may be overconfident absent interim OS curves. Historical parallels: delayed oncology trials sometimes preceded negative outcomes (ADC toxicity or late crossover); unintended consequence of approval could be aggressive payer negotiation, capping near-term revenue despite long-term label expansion.

Key Decisions for Investors

• Establish a 2.0–3.0% long position in AZN (LSE:AZN) at current levels (~14,700p) targeting 18,000p within 6–12 months; set hard stop-loss at 13,000p and trim 50% at 17,000p to lock partial gains.
• Buy a defined-risk Jan 2027 AZN 15,000/20,000p bull call spread (size = 25–50% of the equity notional) to capture upside from an H2 2026 readout while capping premium paid; roll if readout delayed past Q4 2026.
• Implement a relative-value pair: long AZN 2.0% vs short MRK 0.8% (delta-adjust to oncology exposure) to isolate AVANZAR-specific upside; reduce short if MRK shows unrelated strength or AZN volatility collapses.
• Purchase protective AZN puts (6–9 month, ~12,000p) sized at 0.5–1.0% of portfolio to hedge trial/timing risk; liquidate hedge if Jefferies’ P(success) falls >10 percentage points or company confirms readout pushed beyond 31 Dec 2026.